Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.50% | -126.00% | 39.53% | 1.55% | 19.26% |
| Total Depreciation and Amortization | 21.97% | 4.09% | -5.68% | 7.35% | 5.30% |
| Total Amortization of Deferred Charges | 3.14% | -1.24% | 1.90% | -50.16% | -52.47% |
| Total Other Non-Cash Items | 6.58% | 67.69% | -59.83% | 33.21% | 19.58% |
| Change in Net Operating Assets | -168.10% | 323.39% | -183.81% | 159.63% | -48.17% |
| Cash from Operations | -59.19% | -10.97% | -1,883.27% | 103.23% | 25.25% |
| Capital Expenditure | -271.90% | -70.42% | -22.41% | -346.15% | 96.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -271.90% | -70.42% | -22.41% | -346.15% | 96.15% |
| Total Debt Issued | 0.00% | 0.00% | 0.00% | -63.16% | -- |
| Total Debt Repaid | -0.76% | -0.19% | 0.17% | 63.29% | -47,906.48% |
| Issuance of Common Stock | 239.63% | -22.31% | -17.50% | -42.50% | 20.74% |
| Repurchase of Common Stock | 69.53% | -790.90% | -23.99% | 5.18% | 79.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.13% | -10.32% | -12.87% | 57.60% | -137.42% |
| Cash from Financing | 1,508.08% | -81.73% | -22.96% | -38.43% | 18.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.71% | -662.16% | -110.51% | 956.79% | 114.58% |